Publications by authors named "Linda K Buckett"

11Publications

Identification and design of a novel series of MGAT2 inhibitors.

Bioorg Med Chem Lett 2013 May 27;23(9):2721-6. Epub 2013 Feb 27.

AstraZeneca R&D, Cardiovascular & Gastrointestinal Innovative Medicines Unit Mölndal, SE-431 83 Mölndal, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2013.02.084DOI Listing
May 2013

Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats.

J Lipid Res 2013 May 28;54(5):1369-84. Epub 2013 Feb 28.

Physiology and Behavior Laboratory, Institute of Food, Nutrition, and Health, Swiss Federal Institute of Technology, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1194/jlr.M035154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622331PMC
May 2013

ACAT-selective and nonselective DGAT1 inhibition: adrenocortical effects--a cross-species comparison.

Toxicol Pathol 2013 20;41(7):941-50. Epub 2013 Feb 20.

1Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0192623313477753DOI Listing
June 2014

DGAT1 inhibitors as anti-obesity and anti-diabetic agents.

Curr Opin Drug Discov Devel 2010 Jul;13(4):489-96

AstraZeneca plc, Mereside, Alderley Park, Macclesfield, Cheshire, UK.

View Article

Download full-text PDF

Source
July 2010

Diacylglycerol acyltransferases: Potential roles as pharmacological targets.

Pharmacol Ther 2008 Jun 11;118(3):295-302. Epub 2008 Apr 11.

Clinical Sciences Research Institute, Warwick Medical School, Coventry CV4 7AL, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2008.03.010DOI Listing
June 2008